Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo

British Journal of Anaesthesia

Volumn 111, Issue 6, 2013, Pages 1004-1012

  Weber, M L ^a   Chen, C ^b   Li, Y ^b   Farooqui, M ^b   Nguyen, J ^b   Poonawala, T ^b   Hebbel, R P ^b   Gupta, K ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Morphine; Nephropathy; Pain; Platelet derived growth factor; Sickle cell disease

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; MU OPIATE RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MESANGIUM CELL; MICTURITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; SICKLE CELL ANEMIA; TRANSGENIC MOUSE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WESTERN BLOTTING;

EID: 84887923178     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet221     Document Type: Article

References (42)

1. McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related qualityof life in sickle cell patients: The PiSCES project. Health Qual Life Outcomes 2005; 3: 50.
2. Anie KA, Grocott H, White L, Dzingina M, Rogers G, Cho G. Patient self-assessment of hospital pain, mood and healthrelated quality of life in adults with sickle cell disease. BMJ Open 2012; 2.
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-44.
4. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376: 2018-31.
5. Ballas SK.Updateonpainmanagementin sickle cell disease.Hemoglobin 2011; 35: 520-9.
6. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: A critical reappraisal. Blood 2012; 120: 3647-56.
7. Weber ML, Farooqui M, Nguyen J, et al. Morphine induces mesangial cell proliferation and glomerulopathy via kappa-opioid receptors. Am J Physiol Renal Physiol 2008; 294: F1388-97.
8. Arerangaiah R, Chalasani N, Udager AM, et al. Opioids induce renal abnormalities in tumor-bearing mice. Nephron Exp Nephrol 2007; 105: 80-9.
9. Weber ML, Vang D, Velho PE, et al. Morphine promotes renal pathology in sickle mice. Int J Nephrol Renovasc Dis 2012; 5: 109-18.
10. Singhal PC, Sharma P, Gibbons N, Franki N, Kapasi A, Wagner JD. Effect of morphine on renomedullary interstitial cell proliferation and matrix accumulation. Nephron 1997; 77: 225-34.
11. Singhal PC, Sharma P, Sanwal V, et al. Morphine modulates proliferation of kidney fibroblasts. Kidney Int 1998; 53: 350-7.
12. Singhal PC, Gibbons N, Abramovici M. Long termeffects of morphine on mesangial cell proliferation and matrix synthesis. Kidney Int 1992; 41: 1560-70.
13. Gupta M, Yunfang L, Gupta K. Opioids as promoters and regulators of angiogenesis. In: Maragoudakis ME, Papadimitriou E, eds. Angiogenesis: Basic Science and Clinical Applications. Kerala, India: Transworld Research Network, 2007; 303-18.
14. Gupta K, Stephenson EJ. Existence and modus operandii of opioid receptors in endothelium. In: Aird WC, ed. The Endothelium: AComprehensive Reference. New York: Cambridge University Press, 2007; 451-60.
15. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival-unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56: 351-69.
16. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signalling and promotes breast tumor growth. Cancer Res 2002; 62: 4491-8.
17. Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signalling in mouse retinal endothelial cells. Curr Neurovasc Res 2006; 3: 171-80.
18. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 2006; 72: 3-11.
19. Luk K, Boatman S, Johnson KN, et al. Influence of morphine on pericyte-endothelial interaction: implications for antiangiogenic therapy. J Oncol 2012; 2012: 458385.
20. Floege J, Ostendo T, Wolf G. Growth factors and cytokines. In: Neilsen EG, Couser WG, eds. Immunologic Renal Disease, 2nd Edn. Baltimore: Lippincott, Williams and Wilkins, 2001.
21. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997; 278: 876-78.
22. Diwan BA, Gladwin MT, Noguchi CT, Ward JM, Fitzhugh AL, Buzard GS. Renal pathology in hemizygous sickle cell mice. Toxicol Pathol 2002; 30: 254-62.
23. Kohli DR, Li Y, Khasabov SG, et al. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood 2010; 116: 456-65.
24. Quirion R, Finkel MS, Mendelsohn FA, Zamir N. Localization of opiate binding sites in kidney and adrenal gland of the rat. Life Sci 1983; 33(Suppl. 1): 299-302.
25. Neidle A, Manigault I, Wajda IJ. Distribution of opiate-like substances in rat tissues. Neurochem Res 1979; 4: 399-410.
26. Singhal PC, Pan CQ, Sagar S, Gibbons N, Valderrama E. Morphine enhances deposition of ferritin-antiferritin complexes in the glomerular mesangium. Nephron 1995; 70: 229-34.
27. Takahashi T, Abe H, Arai H, et al. Activation of STAT3/Smad1 is a key signalling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J Biol Chem 2005; 280: 7100-6.
28. Grande MT, Lopez-Novoa JM. Therapeutical relevance of MAPkinase inhibitors in renal diseases: current knowledge and future clinical perspectives. Curr Med Chem 2008; 15: 2054-70.
29. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19: 12-23.
30. Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 2011; 113: 1353-64.
31. Singleton PA, Garcia JG, Moss J. Synergistic effects ofmethylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 2008; 7: 1669-79.
32. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007; 97: 1523-31.
33. Wen H, Lu Y, Yao H, Buch S. Morphine induces expression of plateletderived growth factor in human brain microvascular endothelial cells: implication for vascular permeability. PLoS One 2011; 6: e21707.
34. Hostetter TH. Hypeiltration and glomerulosclerosis. Semin Nephrol 2003; 23: 194-9.
35. Atici S, Cinel I, Cinel L, Doruk N, Eskandari G, Oral U. Liver and kidney toxicity in chronic use of opioids: An experimental long term treatment model. J Biosci 2005; 30: 245-52.
36. Gentili M, Bonnet F. Spinal clonidine produces less urinary retention than spinal morphine. Br J Anaesth 1996; 76: 872-3.
37. Mahinda TB, Lovell BM, Taylor BK. Morphine-induced analgesia, hypotension, and bradycardia are enhanced in hypertensive rats. Anesth Analg 2004; 98: 1698-704.
38. Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist norbinaltorphimine. Mol Pharmacol 1995; 47: 1089-94.
39. Beattie DT, Cheruvu M, Mai N, et al. The in vitro pharmacology of the peripherally restricted opioid receptorantagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 205-20.
40. Majumdar S, Grinnell S, Le Rouzic V, et al. Truncated G proteincoupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci USA 2011; 108: 19778-83.
41. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700.
42. Wang X, LoramLC, Ramos K, et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci USA 2012; 109: 6325-30.